Be ready for the possible transition from RRMS to SPMS by understanding new symptoms, treatment options, and what to discuss ...

A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...

Combining the diabetes medication metformin and the antihistamine clemastine increased myelin repair in people with RRMS, ...

Insights from ECTRIMS 2025, including anticipated presentations, key takeaways, and how emerging research on DMTs in RRMS may ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

Having inactive secondary progressive multiple sclerosis can be confusing. Relapses may stop, but symptoms persist. Get ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...

Please provide your email address to receive an email when new articles are posted on . Study examined 41 individuals with RRMS and 20 healthy controls required to wear accelerometer for 1 week.

Fasting and ketogenic diets were found to benefit blood fats, weight, and blood pressure in MS, but did not reduce brain ...